Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sukaina Virji

Sukaina has been reporting on all aspects of the pharmaceutical and biotechnology space since 2000. In her role as News Editor, she is tasked with ensuring Scrip Intelligence continues to provide the business critical information that its subscribers rely on. Sukaina's prior positions include Editor of the newsletter BioVenture View and the magazine BioPeople. She has a PhD in biochemistry and molecular biology from University College London. Based in the UK, Sukaina is often asked to appear on TV and radio to commentate on business and R&D strategy related to the industry.
Advertisement
Set Alert for Articles By Sukaina Virji

Latest From Sukaina Virji

NICE Move On Cabometyx Gives BMS Longer To Make Opdivo Case In Second Line RCC

A NICE knock-back for Ipsen's Cabometyx in renal cell carcinoma (RCC) means less pressure on BMS's embattled Opdivo, but not for long if Ipsen is willing to compromise on price, warn analysts.

Reimbursement Commercial

Breathing Room For BMS In Renal Cancer As Early Tecentriq Data Mixed

Latecomer Tecentriq from Roche has been making solid in roads in the lung cancer space, where it has been scrapping it out with Bristol-Myers Squibb's Opdivo and Merck & Co's Keytruda. However, early data with Tecentriq in the renal cell carcinoma (RCC) space are less than impressive. The news will be welcomed by BMS, which has Opdivo approved in advanced RCC.

Research & Development Cancer

M&A Analysis Reveals Mid Pharma Purchase Preferences

Immunology- and inflammation-focused biotech companies wondering if a trade exit is in their future will be interested to read that, according to a report from Datamonitor Healthcare, their demographic is the most popular acquisition target of the mid-size pharma cohort.

Commercial Deals

AstraZeneca/Chi-Med Set For 'Selective' Pivotal Renal Cell Cancer Trial

Chi-Med is on course to successfully hit the first of a series of value inflection points slated for 2017. Savolitinib, an inhibitor of c-Met receptor tyrosine kinase partnered with AstraZeneca, has shown early clinical benefit in multiple cancers including a large subset of renal cell carcinoma, and a pivotal Phase III trial is now being planned.

Research & Development Cancer

Ipsen Shores Up Cash-Generating Primary Care Business With Sanofi CHC Buy

Ipsen has picked up five of Sanofi's consumer healthcare products in certain European markets to enable the larger company's deal with Boehringer Ingelheim to proceed. Despite moves by Ipsen to bolster its cash-generating primary care business, some analysts still believe a sale could make good business sense.

Commercial Business Strategies

Concerned About Unsustainable Cancer Drug Prices? Here's An Idea

A group of leading researchers are suggesting that using academic centers to de-risk cancer drug discovery could tackle the problem of 'unsustainable drug prices'.

Research & Development Cancer
See All
Advertisement
UsernamePublicRestriction

Register